Google Secures Pentagon AI Deal for Classified Projects 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
PRINCETON, N.J., May 03, 2017 -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at the interactive ePoster session during the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) being held May 6 - 9, 2017 in San Diego, CA.
The SECURE study evaluated the clinical benefit of the investigational transdermal contraceptive patch AG200-15, known as Twirla®, in a diverse, real-world population of women reflective of current weight trends in the United States. The ePoster will include efficacy and safety findings for the overall population and pre-specified body mass index (BMI) categories, in addition to results on the bleeding profile that have not previously reported.
The presentation details are as follows:
| Poster Title: | Results from the SECURE Trial, a Phase 3 Study of the AG200-15 |
| Investigational Transdermal Contraceptive Patch | |
| Poster ID: | 22A |
| Poster Session: | ePoster Session A |
| Room: | Ballroom 20A |
| Date and Time: | Saturday, May 6, 2017 |
| Time: | 11:00 am – 12:00 pm PT |
| Presenter: | Anita Nelson, MD, Professor and Chair, Obstetrics and Gynecology, |
| College of Osteopathic Medicine of the Pacific |
For more information, please visit the company website at www.agiletherapeutics.com.
About Agile Therapeutics, Inc.
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. The company may occasionally disseminate material, nonpublic information on the company website.
Source: Agile Therapeutics
Investor Relations Contact: Mary Coleman Agile Therapeutics 609-356-1921 [email protected] Media Relations Contact: Glenn Silver Lazar Partners Ltd. 646-871-8485 [email protected]
